Omeros PE Ratio 2010-2024 | OMER
Current and historical p/e ratio for Omeros (OMER) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Omeros PE ratio as of January 21, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Omeros PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-01-17 | 9.33 | 0.00 | |
| 2024-09-30 | 3.97 | $-2.31 | 0.00 |
| 2024-06-30 | 4.06 | $-2.35 | 0.00 |
| 2024-03-31 | 3.45 | $-1.97 | 0.00 |
| 2023-12-31 | 3.27 | $-1.88 | 0.00 |
| 2023-09-30 | 2.92 | $0.32 | 9.13 |
| 2023-06-30 | 5.44 | $0.64 | 8.50 |
| 2023-03-31 | 4.65 | $0.74 | 6.28 |
| 2022-12-31 | 2.26 | $0.75 | 3.01 |
| 2022-09-30 | 3.15 | $3.18 | 0.99 |
| 2022-06-30 | 2.75 | $3.10 | 0.89 |
| 2022-03-31 | 6.01 | $3.13 | 1.92 |
| 2021-12-31 | 6.43 | $3.09 | 2.08 |
| 2021-09-30 | 13.79 | $-1.99 | 0.00 |
| 2021-06-30 | 14.84 | $-2.29 | 0.00 |
| 2021-03-31 | 17.80 | $-2.44 | 0.00 |
| 2020-12-31 | 14.29 | $-2.40 | 0.00 |
| 2020-09-30 | 10.11 | $-2.38 | 0.00 |
| 2020-06-30 | 14.72 | $-2.05 | 0.00 |
| 2020-03-31 | 13.37 | $-1.73 | 0.00 |
| 2019-12-31 | 14.09 | $-1.70 | 0.00 |
| 2019-09-30 | 16.33 | $-1.60 | 0.00 |
| 2019-06-30 | 15.69 | $-2.08 | 0.00 |
| 2019-03-31 | 17.37 | $-2.49 | 0.00 |
| 2018-12-31 | 11.14 | $-2.61 | 0.00 |
| 2018-09-30 | 24.41 | $-2.47 | 0.00 |
| 2018-06-30 | 18.14 | $-1.82 | 0.00 |
| 2018-03-31 | 11.17 | $-1.45 | 0.00 |
| 2017-12-31 | 19.43 | $-1.17 | 0.00 |
| 2017-09-30 | 21.62 | $-1.28 | 0.00 |
| 2017-06-30 | 19.91 | $-1.46 | 0.00 |
| 2017-03-31 | 15.12 | $-1.45 | 0.00 |
| 2016-12-31 | 9.92 | $-1.65 | 0.00 |
| 2016-09-30 | 11.16 | $-1.72 | 0.00 |
| 2016-06-30 | 10.52 | $-1.91 | 0.00 |
| 2016-03-31 | 15.34 | $-2.03 | 0.00 |
| 2015-12-31 | 15.73 | $-2.00 | 0.00 |
| 2015-09-30 | 10.96 | $-2.09 | 0.00 |
| 2015-06-30 | 17.99 | $-2.10 | 0.00 |
| 2015-03-31 | 22.03 | $-2.19 | 0.00 |
| 2014-12-31 | 24.78 | $-2.22 | 0.00 |
| 2014-09-30 | 12.72 | $-1.66 | 0.00 |
| 2014-06-30 | 17.40 | $-1.58 | 0.00 |
| 2014-03-31 | 12.07 | $-1.53 | 0.00 |
| 2013-12-31 | 11.29 | $-1.39 | 0.00 |
| 2013-09-30 | 9.75 | $-1.64 | 0.00 |
| 2013-06-30 | 5.04 | $-1.69 | 0.00 |
| 2013-03-31 | 4.12 | $-1.59 | 0.00 |
| 2012-12-31 | 5.19 | $-1.59 | 0.00 |
| 2012-09-30 | 9.40 | $-1.75 | 0.00 |
| 2012-06-30 | 10.00 | $-1.53 | 0.00 |
| 2012-03-31 | 9.93 | $-1.45 | 0.00 |
| 2011-12-31 | 3.95 | $-1.39 | 0.00 |
| 2011-09-30 | 4.05 | $-1.28 | 0.00 |
| 2011-03-31 | 8.00 | $-1.35 | 0.00 |
| 2010-12-31 | 8.24 | $-1.36 | 0.00 |
| 2010-09-30 | 7.29 | $-1.30 | 0.00 |
| 2010-06-30 | 7.42 | $-1.19 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.541B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $196.826B | 25.11 |
| Stryker (SYK) | United States | $146.166B | 32.94 |
| Boston Scientific (BSX) | United States | $145.408B | 41.81 |
| EssilorLuxottica (ESLOY) | France | $115.383B | 0.00 |
| Medtronic (MDT) | Ireland | $112.944B | 16.78 |
| Lonza Group Ag (LZAGY) | Switzerland | $43.849B | 0.00 |
| Haleon (HLN) | United Kingdom | $41.827B | 27.18 |
| GE HealthCare Technologies (GEHC) | United States | $38.715B | 20.08 |
| ResMed (RMD) | United States | $35.199B | 28.92 |
| Terumo (TRUMY) | Japan | $27.980B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $24.250B | 18.56 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.811B | 13.89 |
| Insulet (PODD) | United States | $19.347B | 77.04 |
| Baxter (BAX) | United States | $15.818B | 10.29 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.057B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.586B | 32.58 |
| BellRing Brands (BRBR) | United States | $9.323B | 37.51 |
| Demant (WILYY) | Denmark | $8.735B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.360B | 14.78 |
| ICU Medical (ICUI) | United States | $4.012B | 38.20 |
| Prestige Consumer Healthcare (PBH) | United States | $3.882B | 19.31 |
| Haemonetics (HAE) | United States | $3.691B | 18.01 |
| Envista Holdings (NVST) | United States | $3.413B | 25.42 |
| Perrigo (PRGO) | Ireland | $3.252B | 9.57 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.807B | 18.07 |
| GN Store Nord (GNNDY) | Denmark | $2.585B | 16.58 |
| Neogen (NEOG) | United States | $2.508B | 28.90 |
| LeMaitre Vascular (LMAT) | United States | $2.227B | 54.13 |
| AtriCure (ATRC) | United States | $1.876B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.572B | 27.52 |
| AdaptHealth (AHCO) | United States | $1.416B | 10.11 |
| InMode (INMD) | Israel | $1.410B | 8.48 |
| BioLife Solutions (BLFS) | United States | $1.213B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.205B | 0.00 |
| Owens & Minor (OMI) | United States | $1.124B | 8.78 |
| Curaleaf Holdings (CURLF) | Canada | $0.981B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.843B | 14.87 |
| CeriBell (CBLL) | United States | $0.754B | 0.00 |
| Evolus (EOLS) | United States | $0.666B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.623B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.557B | 24.58 |
| Surmodics (SRDX) | United States | $0.527B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.434B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.434B | 0.00 |
| ZimVie (ZIMV) | United States | $0.394B | 33.23 |
| Valneva SE (VALN) | France | $0.355B | 0.00 |
| Quanterix (QTRX) | United States | $0.342B | 0.00 |
| Cerus (CERS) | United States | $0.332B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.317B | 30.18 |
| Biote (BTMD) | United States | $0.306B | 6.71 |
| Sanara MedTech (SMTI) | United States | $0.285B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.272B | 18.25 |
| High Tide (HITI) | Canada | $0.250B | 103.00 |
| Zynex (ZYXI) | United States | $0.245B | 51.20 |
| Canopy Growth (CGC) | Canada | $0.237B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.226B | 3.18 |
| Aurora Cannabis (ACB) | Canada | $0.211B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.211B | 14.56 |
| Organigram Holdings (OGI) | Canada | $0.196B | 0.00 |
| Brainsway (BWAY) | Israel | $0.192B | 102.30 |
| MacroGenics (MGNX) | United States | $0.188B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.168B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.150B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.149B | 18.77 |
| Veru (VERU) | United States | $0.143B | 0.00 |
| Jin Medical (ZJYL) | China | $0.143B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.130B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.87 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.092B | 0.00 |
| INLIF (INLF) | $0.078B | 0.00 | |
| InterCure (INCR) | Israel | $0.077B | 0.00 |
| Exagen (XGN) | United States | $0.070B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.069B | 35.33 |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.058B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.056B | 0.00 |
| Apyx Medical (APYX) | United States | $0.052B | 0.00 |
| ImmuCell (ICCC) | United States | $0.049B | 0.00 |
| Modular Medical (MODD) | United States | $0.042B | 0.00 |
| Safety Shot (SHOT) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.017B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 14.11 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |